Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ANG-015 / MLU-3 (CHARTER Study): Characterization of Circulating Tumor Cells Isolated Using the Parsortix® System in High Risk and Early Metastatic Prostate Cancer Patients

NCT05437679 is registered in ClinicalTrials.gov with Angle plc as lead sponsor.

NCT NCT05437679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05437679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ANG-015 / MLU-3 (CHARTER Study): Characterization of Circulating Tumor Cells Isolated Using the Parsortix® System in High Risk and Early Metastatic Prostate Cancer Patients
Lead sponsor
Angle plc
Phase
Observational
Overall status
Terminated
Start date
July 5, 2022
Completion date
August 22, 2023
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

biochemically recurrent prostate carcinoma, castration-resistant prostate cancer, high risk prostate carcinoma, prostate cancer